Page 215 - Aet News Today

Whether it was Amazon's buy of One Medical or CVS Health's acquisition of Signify Health, retailers made waves in healthcare this year. Across all of the deals, it's clear that expanding access to medical services is the key goal, experts said. And this is only the beginning.

Healthcare journalists source a significant amount of the stories they write from emailed pitches. To make the media relations process more fruitful for everyone involved, I laid out my top seven pet peeves as a healthcare technology reporter so public relations representatives have a better understanding of which behavior to avoid.

With the projection that the U.S. may spend up to $27.9 billion annually on low-value screening, testing, and procedures considered waste, there needs to be a new approach to how the lab industry develops test menus from which physicians order labs.

One’s bank, for example, doesn’t ask a customer to download and mange three different apps for checking, savings and loan accounts. Today more than ever, “screen creep” is setting in amidst an increasingly frustrated healthcare consumer base.

Kite, the cell therapy unit of Gilead Sciences, is adding more tools to its cell therapy toolbox with the acquisition of Tmunity Therapeutics. It’s the company’s second cell therapy deal this month, following a partnership announced with clinical-stage Arcellx.

In most cases, healthcare organizations choose not to let employees go following an RPA implementation. Instead, they reallocate their (human) resources where they can be better used, boosting employee satisfaction and easing staff burnout.

CMS is to be recognized for taking action to establishing chaplaincy codes along with other core services so that  hospice claims data on spiritual care can be collected.

Through effective and purposeful engagement, frontline caregivers are able to build meaningful relationships with patients, show them that they are seen and heard, and empower them with the information and education they need to be better stewards of their own health.

By 2050 the cost of dementia in the US alone could rise to $1.1 trillion per year. Now more than ever it is critical to address the needs of individuals and families living with dementia. Fortunately, new diagnostic and treatment discoveries are paving the way for significant advancements.

Historically, clinical trials have not prioritized the experiences of patients, who are required to frequently return on-site and engage with unfamiliar medical technology. They are often left in the dark regarding the data and health outcomes being collected through their participation.